Cardiac remodeling remains a critical prognostic factor in patients surviving myocardial infarction. It also complicates chronic conditions like diabetes and arterial hypertension. Recent research into cannabinoids and cardiac remodeling highlights their potential to mitigate pathological changes in heart structure. Consequently, medical educators now focus on these compounds due to their robust anti-inflammatory and antioxidant properties. These substances may influence pro-fibrotic signaling and inhibit the excessive deposition of the extracellular matrix. Moreover, this modulation offers a novel approach to managing heart failure progression.

Therapeutic Potential of Cannabinoids and Cardiac Remodelling

The endocannabinoid system (ECS) plays a vital role in maintaining cardiovascular homeostasis. Specifically, scientists have identified cannabinoid type 2 (CB2) receptor activation as a promising pathway for cardioprotection. In contrast, blocking the peripheral cannabinoid type 1 (CB1) receptor appears to prevent adverse structural changes. Furthermore, these interventions limit the progression of fibrotic lesions by restoring normal molecular signaling. Therefore, modulating the ECS could revolutionize the treatment of heart failure and related chronic diseases. For instance, selective agonists can target specific pathways without central nervous system side effects. Additionally, these therapies may supplement existing treatments for arterial hypertension.

How do cannabinoids prevent cardiac fibrosis?

Cannabinoids prevent fibrosis by inhibiting pro-fibrotic signaling pathways and reducing oxidative stress. Consequently, they help restore the balance of extracellular matrix deposition in the myocardium.

Are specific receptors more important for heart health?

Yes, research suggests that activating the CB2 receptor and blocking peripheral CB1 receptors offer the most significant cardioprotective benefits. This dual approach helps limit inflammation and prevents structural remodeling.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Doctors should always exercise their clinical judgment and tailor treatment to individual patient needs. Refer to the latest local and national guidelines for clinical practice.

References

1. Krzyżewska A et al. The relationship between the cannabinoids and cardiac remodelling: A comprehensive review of pivotal mechanisms and emerging evidence. Br J Pharmacol. 2026 Feb 09. doi: 10.1111/bph.70347. PMID: 41662725.


2. Urlić H et al. Cardiovascular Effects of Cannabidiol: From Molecular Mechanisms to Clinical Implementation. Int J Mol Sci. 2025 Oct 01. doi: 10.3390/ijms26199610.


3. Chandy M et al. The relationship between cannabis and cardiovascular disease: clearing the haze. Nat Rev Cardiol. 2025 Jan 23. doi: 10.1038/s41569-025-01121-6.